vlv75's Top Recommendations

These recommendations were last updated about an hour ago.

	Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. [My Copy] Pharmaceutical research, Vol. 25, No. 6. (June 2008), pp. 1469-1483. by J. Kamiie, S. Ohtsuki, R. Iwase, et al.K. Ohmine, Y. Katsukura, K. Yanai, Y. Sekine, Y. Uchida, S. Ito, T. Terasaki posted by 2 people cgeneraux guhjy
	Molecular physiology of renal organic anion transporters [My Copy] Am J Physiol Renal Physiol, Vol. 290, No. 2. (1 February 2006), pp. F251-261. by Takashi Sekine, Hiroki Miyazaki, Hitoshi Endou posted by 1 person guhjy
	The current state of serum biomarkers of hepatotoxicity. [My Copy] Toxicology, Vol. 245, No. 3. (20 March 2008), pp. 194-205. by J. Ozer, M. Ratner, M. Shaw, W. Bailey, S. Schomaker posted by 2 people cgeneraux guhjy
	Gene expression and regulation of drug transporters in the intestine and kidney. [My Copy] Biochem Pharmacol, Vol. 73, No. 3. (1 February 2007), pp. 440-449. by T. Terada, K. Inui posted by 1 person guhjy
	Prediction of human pharmacokinetics renal metabolic and excretion clearance [My Copy] Journal of Pharmacy and Pharmacology, Vol. 59, No. 11. (November 2007), pp. 1463-1471. by Fagerholm, Urban posted by 1 person guhjy
	IN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATES [My Copy] Drug Metabolism and Disposition, Vol. 34, No. 5. (May 2006), pp. 786-792. by Jarkko Rautio, Joan E. Humphreys, Lindsey O. Webster, et al.Anand Balakrishnan, John P. Keogh, Jeevan R. Kunta, Cosette J. Serabjit-Singh, Joseph W. Polli
	Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux [My Copy] British Journal of Pharmacology, Vol. 151, No. 5. (2007), pp. 701-712. by D. Groenendaal, J. Freijer, D. Mik, M. R. Bouw, M. Danhof, E. C. M. Lange
	Transport of bile acids in a human intestinal epithelial cell line, Caco-2 [My Copy] Biochimica et Biophysica Acta (BBA) - General Subjects, Vol. 1035, No. 1. (20 July 1990), pp. 97-103. by I. Hidalgo, R. Borchardt
	Efflux of Taurocholic Acid Across the Blood-Brain Barrier: Interaction with Cyclic Peptides [My Copy] J Pharmacol Exp Ther, Vol. 286, No. 2. (1 August 1998), pp. 890-895. by Takeo Kitazawa, Tetsuya Terasaki, Hiroshi Suzuki, Atsuyuki Kakee, Yuichi Sugiyama
	The SLC16 monocaboxylate transporter family [My Copy] Xenobiotica: The fate and safety evaluation of foreign compounds in biological systems, Vol. 38, No. 7. (2008), pp. 1072-1106. by D. Meredith, H. C. Christian
	The SLC16 gene family—from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond [My Copy] Pflügers Archiv European Journal of Physiology, Vol. 447, No. 5. (1 February 2004), pp. 619-628. by Andrewp Halestrap, David Meredith
	ALTERED HEPATOBILIARY DISPOSITION OF 5 (AND 6)-CARBOXY-2',7'-DICHLOROFLUORESCEIN IN Abcg2 (Bcrp1) AND Abcc2 (Mrp2) KNOCKOUT MICE [My Copy] Drug Metab Dispos, Vol. 34, No. 4. (1 April 2006), pp. 718-723. by Ken-Ichi Nezasa, Xianbin Tian, Maciej J. Zamek-Gliszczynski, Nita J. Patel, Thomas J. Raub, Kim L. R. Brouwer
	Multidrug Resistance-Associated Protein 2 Is Primarily Responsible for the Biliary Excretion of Fexofenadine in Mice [My Copy] Drug Metab Dispos, Vol. 36, No. 1. (1 January 2008), pp. 61-64. by Xianbin Tian, Maciej J. Zamek-Gliszczynski, Jun Li, et al.Arlene S. Bridges, Ken-Ichi Nezasa, Nita J. Patel, Thomas J. Raub, Kim L. R. Brouwer
	Differential Involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in Biliary Excretion of 4-Methylumbelliferyl Glucuronide and Sulfate in the Rat [My Copy] J Pharmacol Exp Ther, Vol. 319, No. 1. (1 October 2006), pp. 459-467. by Maciej J. Zamek-Gliszczynski, Keith A. Hoffmaster, Joan E. Humphreys, Xianbin Tian, Ken-Ichi Nezasa, Kim L. R. Brouwer
	Contrasting Influence of NADPH and a NADPH-Regenerating System on the Metabolism of Carbonyl-Containing Compounds in Hepatic Microsomes [My Copy] Drug Metab Dispos, Vol. 37, No. 9. (1 September 2009), pp. 1801-1805. by Christopher S. Mazur, John F. Kenneke, Michael-Rock Goldsmith, Cather Brown
	Relationship between Drug/Metabolite Exposure and Impairment of Excretory Transport Function [My Copy] Drug Metab Dispos, Vol. 37, No. 2. (1 February 2009), pp. 386-390. by Maciej J. Zamek-Gliszczynski, J. Cory Kalvass, Gary M. Pollack, Kim L. R. Brouwer
	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds [My Copy] Drug Metab Dispos, Vol. 36, No. 7. (1 July 2008), pp. 1385-1405. by R. Scott Obach, Franco Lombardo, Nigel J. Waters
	Functional Consequences of Single Nucleotide Polymorphisms in the Human Organic Anion Transporter hOAT1 (SLC22A6) [My Copy] J Pharmacol Exp Ther, Vol. 314, No. 2. (1 August 2005), pp. 923-931. by Kelly Bleasby, Laura A. Hall, Jennifer L. Perry, Harvey W. Mohrenweiser, John B. Pritchard posted by 2 people Asian Pharmacogenetics Library shin38jp
	Hepatobiliary Disposition in Primary Cultures of Dog and Monkey Hepatocytes [My Copy] Molecular Pharmaceutics, Vol. 3, No. 3. (1 June 2006), pp. 266-274. by Kelly A. Rose, Vsevolod Kostrubsky, Jasminder Sahi
	Contribution of Sodium Taurocholate Co-Transporting Polypeptide to the Uptake of Its Possible Substrates Into Rat Hepatocytes [My Copy] J Pharmacol Exp Ther, Vol. 286, No. 2. (1 August 1998), pp. 1043-1050. by Hirokazu Kouzuki, Hiroshi Suzuki, Kousei Ito, Rui Ohashi, Yuichi Sugiyama
	Function of Uptake Transporters for Taurocholate and Estradiol 17β-D-Glucuronide in Cryopreserved Human Hepatocytes [My Copy] Drug Metabolism and Pharmacokinetics, Vol. 18, No. 1. (2003), pp. 33-41. by Yoshihisa Shitara, Albert P. Li, Yukio Kato, et al.Chuang Lu, Kiyomi Ito, Tomoo Itoh, Yuichi Sugiyama
	Transport of bile acids in hepatic and non-hepatic tissues [My Copy] J Exp Biol, Vol. 204, No. 10. (15 May 2001), pp. 1673-1686. by M. V. St-Pierre, G. A. Kullak-Ublick, B. Hagenbuch, P. J. Meier
	Physicochemical Determinants of Human Renal Clearance [My Copy] Journal of Medicinal Chemistry, Vol. 0, No. 0. (0000) by Manthena V. Varma, Bo Feng, Scott R. Obach, et al.Matthew D. Troutman, Jonathan Chupka, Howard R. Miller, Ayman El-Kattan
	Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers [My Copy] Clinical Therapeutics, Vol. 25, No. 11. (November 2003), pp. 2822-2835. by P. Martin
	Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers [My Copy] Clinical Therapeutics, Vol. 25, No. 10. (October 2003), pp. 2553-2563. by P. Martin
	Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. [My Copy] The Journal of pharmacology and experimental therapeutics, Vol. 311, No. 1. (1 October 2004), pp. 139-146. by Masaru Hirano, Kazuya Maeda, Yoshihisa Shitara, Yuichi Sugiyama
	Interaction of Oral Antidiabetic Drugs With Hepatic Uptake Transporters [My Copy] Diabetes, Vol. 57, No. 6. (June 2008), pp. 1463-1469. by Iouri Bachmakov, Hartmut Glaeser, Martin F. Fromm, Jörg König
	MODELING OF INTESTINAL DRUG ABSORPTION: ROLES OF TRANSPORTERS AND METABOLIC ENZYMES (FOR THE GILLETTE REVIEW SERIES) [My Copy] Drug Metab Dispos, Vol. 31, No. 12. (1 December 2003), pp. 1507-1519. by Sandy K. Pang
	Effects of Intestinal CYP3A4 and P-Glycoprotein on Oral Drug Absorption—Theoretical Approach [My Copy] Pharmaceutical Research, Vol. 16, No. 2. (21 February 1999), pp. 225-231. by Kiyomi Ito, Hiroyuki Kusuhara, Yuichi Sugiyama
	A Mathematical Simulation to Explain the Coordinated Functions of Efflux and Metabolism Limiting the Transport of Anti-HIV Agents Across Caco-2 Cells [My Copy] American Journal of Therapeutics, Vol. 11, No. 2. (March 2004), pp. 114-123. by Jignesh Patel, Azher Hussain, Dhahanjay Pal, Ashim K. Mitra
	Verapamil P-glycoprotein Transport across the Rat Blood-Brain Barrier: Cyclosporine, a Concentration Inhibition Analysis, and Comparison with Human Data [My Copy] J Pharmacol Exp Ther, Vol. 317, No. 2. (1 May 2006), pp. 704-710. by Peng Hsiao, Lucy Sasongko, Jeanne M. Link, et al.David A. Mankoff, Mark Muzi, Ann C. Collier, Jashvant D. Unadkat
	Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption [My Copy] Journal of Pharmaceutical Sciences, Vol. 98, No. 6. (2009), pp. 2180-2197. by Raj Badhan, Jeffrey Penny, Aleksandra Galetin, Brian J. Houston
	Molecular and Physical Mechanisms of First-Pass Extraction [My Copy] Drug Metab Dispos, Vol. 27, No. 2. (1 February 1999), pp. 161-166. by Stephen D. Hall, Kenneth E. Thummel, Paul B. Watkins, et al.Kenneth S. Lown, Leslie Z. Benet, Mary F. Paine, Robert R. Mayo, Kim D. Turgeon, David G. Bailey, Robert J. Fontana, Steven A. Wrighton
	Elucidating Rifampin's Inducing and Inhibiting Effects on Glyburide Pharmacokinetics and Blood Glucose in Healthy Volunteers: Unmasking the Differential Effects of Enzyme Induction and Transporter Inhibition for a Drug and Its Primary Metabolite [My Copy] Clin Pharmacol Ther, Vol. 85, No. 1. (8 October 2008), pp. 78-85. by H. X. Zheng, Y. Huang, L. A. Frassetto, L. Z. Benet
	Cytochrome P450 Induction by Rifampicin in Healthy Subjects: Determination Using the Karolinska Cocktail and the Endogenous CYP3A4 Marker 4[beta]-Hydroxycholesterol [My Copy] Clin Pharmacol Ther, Vol. 84, No. 5. (23 July 2008), pp. 589-594. by K. P. Kanebratt, U. Diczfalusy, T. Backstrom, et al.E. Sparve, E. Bredberg, Y. Bottiger, T. B. Andersson, L. Bertilsson
	Rifampicin-induced CYP3A4 activation in CTX patients cannot replace chenodeoxycholic acid treatment [My Copy] Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, Vol. 1771, No. 7. (July 2007), pp. 839-844. by Auryan Szalat, Pavel Gershkovich, Alon Ben-Ari, et al.Aviv Shaish, Yael Liberman, Eti Boutboul, Marc Gotkine, Amnon Hoffman, Dror Harats, Eran Leitersdorf
	Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. [My Copy] BMC cancer, Vol. 4 (22 June 2004) by M. J. Lewis, J. P. Wiebe, J. G. Heathcote posted by 1 person aheibein
	Quantitative prediction of in vivo profiles of CYP3A4 induction in humans from in vitro results with reporter gene assay [My Copy] Drug Metab Dispos (12 March 2009), dmd.108.025734. by Masanari Kozawa, Masashi Honma, Hiroshi Suzuki
	Population-Based Assessments of Clinical Drug-Drug Interactions: Qualitative Indices or Quantitative Measures? [My Copy] J Clin Pharmacol, Vol. 46, No. 11. (1 November 2006), pp. 1268-1289. by Honghui Zhou
	Prediction of the possibility of the secondary peaks of iv bolus drug plasma concentration time curve by the model that directly takes into account the transit time through the organ [My Copy] Journal of Pharmaceutical Sciences, Vol. 9999, No. 9999. (2009), n/a. by Leonid M. Berezhkovskiy
	How important is intestinal cytochrome P450 3A metabolism? [My Copy] Trends in Pharmacological Sciences (28 March 2009) by Antonius E. van Herwaarden, Robert A. van Waterschoot, Alfred H. Schinkel
	Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug-drug interactions: using <I>in vitro</I> data as an aid to assess study power [My Copy] Pharmaceutical Statistics, Vol. 9999, No. 9999. (2009), n/a. by Trevor N. Johnson, Thomas Kerbusch, Barry Jones, Geoffrey T. Tucker, Amin Rostami-Hodjegan, Peter A. Milligan
	Mechanism-based inhibition of cytochrome P450 enzymes: An evaluation of early decision making in vitro approaches and drug–drug interaction prediction methods [My Copy] European Journal of Pharmaceutical Sciences, Vol. 36, No. 2-3. (15 February 2009), pp. 175-191. by K. Grime, J. Bird, D. Ferguson, R. Riley
	ATAZANAVIR: EFFECTS ON P-GLYCOPROTEIN TRANSPORT AND CYP3A METABOLISM IN VITRO [My Copy] Drug Metab Dispos, Vol. 33, No. 6. (1 June 2005), pp. 764-770. by Elke S. Perloff, Su X. Duan, Paul R. Skolnik, David J. Greenblatt, Lisa L. von Moltke
	Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the HIV-1 Integrase Enzyme [My Copy] Drug Metab Dispos (25 June 2007), dmd.107.016196. by Kelem Kassahun, Ian Mcintosh, Donghui Cui, et al.David Hreniuk, Sheila Merschman, Kenneth Lasseter, Neal Azrolan, Marian Iwamoto, John Wagner, Larissa Wenning
	Dose-Response of Ritonavir on Hepatic CYP3A Activity and Elvitegravir Oral Exposure [My Copy] Clin Pharmacol Ther, Vol. 85, No. 1. (24 September 2008), pp. 64-70. by A. A. Mathias, S. West, J. Hui, B. P. Kearney
	Determination of mRNA Expression of Human UDP-Glucuronosyltransferases and Application for Localization in Various Human Tissues by Real-Time Reverse Transcriptase-Polymerase Chain Reaction [My Copy] Drug Metab Dispos, Vol. 37, No. 1. (1 January 2009), pp. 32-40. by Shuji Ohno, Shizuo Nakajin
	Expression of UGT1A and UGT2B mRNA in Human Normal Tissues and Various Cell Lines [My Copy] Drug Metab Dispos, Vol. 36, No. 8. (1 August 2008), pp. 1461-1464. by Akiko Nakamura, Miki Nakajima, Hiroyuki Yamanaka, Ryoichi Fujiwara, Tsuyoshi Yokoi
	Regulation of UDP glucuronosyltransferases in the gastrointestinal tract [My Copy] Toxicology and Applied Pharmacology, Vol. 199, No. 3. (September 2004), pp. 354-363. by P. Gregory
	The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. [My Copy] Drug metabolism reviews, Vol. 33, No. 3-4. (v 2001), pp. 273-297. by M. B. Fisher, M. F. Paine, T. J. Strelevitz, S. A. Wrighton
	Use of Sandwich-Cultured Human Hepatocytes to Predict Biliary Clearance of Angiotensin II Receptor Blockers and HMG-CoA Reductase Inhibitors [My Copy] Drug Metab Dispos, Vol. 37, No. 3. (1 March 2009), pp. 447-452. by Koji Abe, Arlene S. Bridges, Kim L. Brouwer
	Substrate-Dependent Breast Cancer Resistance Protein (Bcrp1/Abcg2)-Mediated Interactions: Consideration of Multiple Binding Sites in in Vitro Assay Design [My Copy] Drug Metab Dispos, Vol. 37, No. 3. (1 March 2009), pp. 560-570. by Nagdeep Giri, Sagar Agarwal, Naveed Shaik, Guoyu Pan, Ying Chen, William F. Elmquist
	Fexofenadine Brain Exposure and the Influence of Blood-Brain Barrier P-Glycoprotein After Fexofenadine and Terfenadine Administration [My Copy] Drug Metab Dispos, Vol. 37, No. 3. (1 March 2009), pp. 529-535. by Rong Zhao, Cory J. Kalvass, Souzan B. Yanni, Arlene S. Bridges, Gary M. Pollack
	The Inhibition of Human Multidrug and Toxin Extrusion 1 Is Involved in the Drug-Drug Interaction Caused by Cimetidine [My Copy] Drug Metab Dispos, Vol. 37, No. 3. (1 March 2009), pp. 555-559. by Soichiro Matsushima, Kazuya Maeda, Katsuhisa Inoue, et al.Kin-Ya Ohta, Hiroaki Yuasa, Tsunenori Kondo, Hideki Nakayama, Shigeru Horita, Hiroyuki Kusuhara, Yuichi Sugiyama
	Effect of OATP1B Transporter Inhibition on the Pharmacokinetics of Atorvastatin in Healthy Volunteers [My Copy] Clin Pharmacol Ther, Vol. 81, No. 2. (27 December 2006), pp. 194-204. by Y. Y. Lau, Y. Huang, L. Frassetto, L. Z. Benet
	Unmasking the dynamic interplay between efflux transporters and metabolic enzymes [My Copy] International Journal of Pharmaceutics, Vol. 277, No. 1-2. (11 June 2004), pp. 3-9. by L. Benet, C. Cummins, C. Wu
	Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin [My Copy] Drug Metab Dispos, Vol. 36, No. 10. (1 October 2008), pp. 2014-2023. by Satoshi Kitamura, Kazuya Maeda, Yi Wang, Yuichi Sugiyama
	Drug-Drug Interactions Mediated Through P-Glycoprotein: Clinical Relevance and In Vitro-In Vivo Correlation Using Digoxin as a Probe Drug [My Copy] Clin Pharmacol Ther, Vol. 85, No. 2. (5 November 2008), pp. 173-181. by K. S. Fenner, M. D. Troutman, S. Kempshall, et al.J. A. Cook, J. A. Ware, D. A. Smith, C. A. Lee
	Role of Hepatic Transporters in the Disposition and Hepatotoxicity of a Her2 Tyrosine Kinase Inhibitor CP-724,714 [My Copy] Toxicol. Sci. (17 February 2009), kfp033. by Bo Feng, Jinghai J. Xu, Yi-An Bi, et al.Rouchelle Mireles, Ralph Davidson, David B. Duignan, Scott Campbell, Vsevolod E. Kostrubsky, Margaret C. Dunn, Arthur R. Smith, Huifen F. Wang
	Dual Mechanisms of CYP3A Protein Regulation by Proinflammatory Cytokine Stimulation in Primary Hepatocyte Cultures [My Copy] Drug Metab Dispos (26 January 2009), dmd.108.026187. by Choon-Myung Lee, Jan Pohl, Edward T. Morgan
	Toward an Increased Understanding of the Barriers to Colonic Drug Absorption in Humans: Implications for Early Controlled Release Candidate Assessment [My Copy] Molecular Pharmaceutics, Vol. 6, No. 1. (2 February 2009), pp. 60-73. by Christer Tannergren, Anna Bergendal, Hans Lennernäs, Bertil Abrahamsson
	High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis [My Copy] Hepatology, Vol. 9999, No. 9999. (2009), NA. by Frank G. Schaap, Niels A. van der Gaag, Dirk J. Gouma, Peter L. M. Jansen
	Hepatobiliary Disposition of Thyroid Hormone in Mrp2-Deficient TR- Rats: Reduced Biliary Excretion of Thyroxine-Glucuronide does not Prevent Xenobiotic-Induced Hypothyroidism [My Copy] Toxicol. Sci. (11 February 2009), kfp026. by Lloyd Lecureux, Matthew Z. Dieter, David M. Nelson, et al.Linda Watson, Harvey Wong, Brian Gemzik, Curtis D. Klaassen, Lois D. Lehman-Mckeeman
	Qualitative Analysis of the Role of Metabolites in Inhibitory Drug−Drug Interactions: Literature Evaluation Based on the Metabolism and Transport Drug Interaction Database [My Copy] Chemical Research in Toxicology, Vol. 22, No. 2. (16 February 2009), pp. 294-298. by Nina Isoherranen, Houda Hachad, Catherine K. Yeung, Rene H. Levy
	The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans [My Copy] Journal of Pharmaceutical Sciences, Vol. 9999, No. 9999. (2009), n/a. by Masayuki Takahashi, Takuo Washio, Norio Suzuki, Katsuhiro Igeta, Shinji Yamashita
	Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors [My Copy] Pharmacoepidemiology and Drug Safety, Vol. 9999, No. 9999. (2009), n/a. by Christopher Rowan, Allen D. Brinker, Parivash Nourjah, et al.Jennie Chang, Andrew Mosholder, Jeffrey S. Barrett, Mark Avigan
	A Model-based Approach to Characterize Efavirenz Autoinduction and Concurrent Enzyme Induction with Carbamazepine [My Copy] Antimicrob. Agents Chemother. (17 February 2009), AAC.01120-08. by Min Zhu, Sanjeev Kaul, Partha Nandy, Dennis M. Grasela, Marc Pfister
	Prediction of Drug Clearance by Glucuronidation from in Vitro Data: Use of Combined Cytochrome P450 and UDP-Glucuronosyltransferase Cofactors in Alamethicin-Activated Human Liver Microsomes [My Copy] Drug Metab Dispos, Vol. 37, No. 1. (1 January 2009), pp. 82-89. by Peter J. Kilford, Rowan Stringer, Bindi Sohal, Brian J. Houston, Aleksandra Galetin
	Relative Importance of Intestinal and Hepatic Glucuronidation—Impact on the Prediction of Drug Clearance [My Copy] Pharmaceutical Research by Helen Cubitt, J. Houston, Aleksandra Galetin
	Cytochrome P450 3A4 and P-glycoprotein Expression in Human Small Intestinal Enterocytes and Hepatocytes: A Comparative Analysis in Paired Tissue Specimens[ast] [My Copy] Clin Pharmacol Ther, Vol. 75, No. 3. (March 2004), pp. 172-183. by Oliver von Richter, Oliver Burk, Martin F. Fromm, Klaus P. Thon, Michel Eichelbaum, Kari T. Kivisto
	THE HUMAN INTESTINAL CYTOCHROME P450 "PIE" [My Copy] Drug Metab Dispos, Vol. 34, No. 5. (1 May 2006), pp. 880-886. by Mary F. Paine, Heather L. Hart, Shana S. Ludington, Robert L. Haining, Allan E. Rettie, Darryl C. Zeldin
	Impact of Basolateral Multidrug Resistance-Associated Protein (Mrp) 3 and Mrp4 on the Hepatobiliary Disposition of Fexofenadine in Perfused Mouse Livers [My Copy] Drug Metab Dispos, Vol. 36, No. 5. (1 May 2008), pp. 911-915. by Xianbin Tian, Brandon Swift, Maciej J. Zamek-Gliszczynski, Martin G. Belinsky, Gary D. Kruh, Kim L. R. Brouwer posted by 1 person cgeneraux
	Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers [My Copy] Clinical Therapeutics, Vol. 28, No. 1. (January 2006), pp. 55-72. by A. Bergman, C. Stevens, Y. Zhou, et al.B. Yi, M. Laethem, M. Desmet, K. Snyder, D. Hilliard, W. Tanaka, W. Zeng
	Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers [My Copy] British Journal of Clinical Pharmacology, Vol. 46, No. 2. (1998), pp. 111-116. by Daniele Ouellet*, Ann Hsu, Jiang Qian, et al.Charles S. Locke, Carolyn J. Eason, John H. Cavanaugh, John M. Leonard, Richard G. Granneman
	Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes [My Copy] Am J Physiol Gastrointest Liver Physiol, Vol. 295, No. 3. (1 September 2008), pp. G570-580. by Rajgopal Govindarajan, Christopher J. Endres, Dale Whittington, et al.Edward Lecluyse, Marcal Pastor-Anglada, Chung-Ming Tse, Jashvant D. Unadkat
	Adamantane sulfone and sulfonamide 11-β-HSD1 Inhibitors [My Copy] Bioorganic & Medicinal Chemistry Letters, Vol. 17, No. 2. (15 January 2007), pp. 527-532. by B. Sorensen, M. Winn, J. Rohde, et al.Q. Shuai, J. Wang, S. Fung, K. Monzon, W. Chiou, D. Stolarik, H. Imade
	Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation [My Copy] Nicotine & Tobacco Research, Vol. 9, No. 8. (2007), pp. 821-833. by Sean P. David, Richard A. Brown, George D. Papandonatos, et al.Christopher W. Kahler, Elizabeth E. Lloyd-Richardson, Marcus R. Munafò, Peter G. Shields, Caryn Lerman, David Strong, Jeanne Mccaffery, Raymond Niaura
	Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species [My Copy] J Mol Endocrinol, Vol. 35, No. 1. (1 August 2005), pp. 89-101. by Spyridon Arampatzis, Bert Kadereit, Daniela Schuster, et al.Zoltan Balazs, Roberto A. Schweizer, Felix J. Frey, Thierry Langer, Alex Odermatt
	Grapefruit juice inhibits 11β-hydroxysteroid dehydrogenase <i>in vivo</i>, in man [My Copy] Clinical Endocrinology, Vol. 59, No. 1. (2003), pp. 143-144.
	Carbonyl Reductases and Pluripotent Hydroxysteroid Dehydrogenases of the Short-chain Dehydrogenase/reductase Superfamily [My Copy] Drug Metabolism Reviews, Vol. 39, No. 1. (2007), pp. 87-144. by Frank Hoffmann, Edmund Maser
	11β-Hydroxysteroid Dehydrogenase Type 1 from Human Liver: Dimerization and Enzyme Cooperativity Support Its Postulated Role as Glucocorticoid Reductase† [My Copy] Biochemistry, Vol. 41, No. 7. (1 February 2002), pp. 2459-2465. by Edmund Maser, Bernhard Volker, Jutta Friebertshauser
	Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases [My Copy] Chemico-Biological Interactions, Vol. 147, No. 2. (March 2004), pp. 129-139. by M. Rosemond
	Expression of the Human CYP3A4 Gene in the Small Intestine of Transgenic Mice: In Vitro Metabolism and Pharmacokinetics of Midazolam [My Copy] Drug Metab Dispos, Vol. 31, No. 5. (1 May 2003), pp. 548-558. by Camille P. Granvil, Ai-Ming Yu, Guillermo Elizondo, et al.Taro E. Akiyama, Connie Cheung, Lionel Feigenbaum, Kristopher W. Krausz, Frank J. Gonzalez
	The Complexities of Hepatic Drug Transport: Current Knowledge and Emerging Concepts [My Copy] Pharmaceutical Research, Vol. 21, No. 5. (1 May 2004), pp. 719-735. by Priyamvada Chandra, Kim Brouwer posted by 1 person cgeneraux
	Carbonyl reductase [My Copy] Chemico-Biological Interactions, Vol. 129, No. 1-2. (1 December 2000), pp. 21-40. by G. Forrest posted by 1 person ggeneraux
	Purification, characterization and NNK carbonyl reductase activities of 11β-hydroxysteroid dehydrogenase type 1 from human liver: enzyme cooperativity and significance in the detoxification of a tobacco-derived carcinogen [My Copy] Chemico-Biological Interactions, Vol. 143-144 (01 February 2003), pp. 435-448. by E. Maser
	Human aldo–keto reductases: Function, gene regulation, and single nucleotide polymorphisms [My Copy] Archives of Biochemistry and Biophysics, Vol. 464, No. 2. (15 August 2007), pp. 241-250. by T. Penning, J. Drury posted by 1 person aheibein
	Carbonyl Reductases: The Complex Relationships of Mammalian Carbonyl- and Quinone-Reducing Enzymes and Their Role in Physiology [My Copy] Annual Review of Pharmacology and Toxicology, Vol. 47, No. 1. (2007), pp. 293-322. by Udo Oppermann posted by 1 person aheibein
	PPARα Agonists Reduce 11β-Hydroxysteroid Dehydrogenase Type 1 in the Liver [My Copy] Biochemical and Biophysical Research Communications, Vol. 279, No. 2. (20 December 2000), pp. 330-336. by A. Hermanowski-Vosatka
	Interindividual variability of carbonyl reductase levels in human livers. [My Copy] Biochemical pharmacology, Vol. 45, No. 8. (22 April 1993), pp. 1711-1714. by N. Iwata, N. Inazu, S. Hara, et al.T. Yanase, S. Kano, T. Endo, F. Kuriiwa, Y. Sato, T. Satoh
	Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine [My Copy] J Pharmacol Exp Ther, Vol. 308, No. 1. (1 January 2004), pp. 189-197. by Tanja Richter, Thomas E. Murdter, Georg Heinkele, et al.Jurgen Pleiss, Stephan Tatzel, Matthias Schwab, Michel Eichelbaum, Ulrich M. Zanger
	Reductases for carbonyl compounds in human liver [My Copy] Biochemical Pharmacology, Vol. 34, No. 1. (01 January 1985), pp. 107-117. by T. Nakayama, A. Hara, K. Yashiro, H. Sawada
	Molecular and structural aspects of xenobiotic carbonyl metabolizing enzymes. Role of reductases and dehydrogenases in xenobiotic phase I reactions [My Copy] Toxicology, Vol. 144, No. 1-3. (3 April 2000), pp. 71-81. by U. Oppermann
	Mechanisms of Disease: selective inhibition of 11[beta]-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome [My Copy] Nat Clin Pract End Met, Vol. 1, No. 2. (December 2005), pp. 92-99. by Jeremy W. Tomlinson, Paul M. Stewart
	Inhibition of 11beta-hydroxysteroid dehydrogenase by bile acids in rats with cirrhosis [My Copy] Hepatology, Vol. 30, No. 3. (1999), pp. 623-629. by Daniel Ackermann, Bruno Vogt, Geneviève Escher, et al.Bernhard Dick, Jürg Reichen, Brigitte M. Frey, Felix J. Frey
	Furosemide inhibits 11 beta-hydroxysteroid dehydrogenase in vitro and in vivo [My Copy] Endocrinology, Vol. 136, No. 4. (1 April 1995), pp. 1759-1765. by G. Escher, K. V. Meyer, B. S. Vishwanath, B. M. Frey, F. J. Frey
	Effect of 17-alpha -Ethynylestradiol on Activities of Cytochrome P450 2B (P450 2B) Enzymes: Characterization of Inactivation of P450s 2B1 and 2B6 and Identification of Metabolites [My Copy] J Pharmacol Exp Ther, Vol. 300, No. 2. (1 February 2002), pp. 549-558. by Ute M. Kent, Danielle E. Mills, Rajendram V. Rajnarayanan, William L. Alworth, Paul F. Hollenberg
	Ritonavir, Efavirenz, and Nelfinavir Inhibit CYP2B6 Activity in Vitro: Potential Drug Interactions with Bupropion [My Copy] Drug Metab Dispos, Vol. 29, No. 2. (1 February 2001), pp. 100-102. by Leah M. Hesse, Lisa L. von Moltke, Richard I. Shader, David J. Greenblatt
	Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation [My Copy] Clin Pharmacol Ther, Vol. 74, No. 4. (October 2003), pp. 326-333. by Sanna Palovaara, Olavi Pelkonen, Jouko Uusitalo, Stefan Lundgren, Kari Laine
	CYP2B6 Mediates the In Vitro Hydroxylation of Bupropion: Potential Drug Interactions with Other Antidepressants [My Copy] Drug Metab Dispos, Vol. 28, No. 10. (1 October 2000), pp. 1176-1183. by Leah M. Hesse, Karthik Venkatakrishnan, Michael H. Court, et al.Lisa L. von Moltke, Su X. Duan, Richard I. Shader, David J. Greenblatt